Effect of Combined Treatment with Voglibose and Sitagliptin on Insulin Resistance in Patients with T2DM
Objective:To observe the effect of combined treatment with Voglibose and Sitagliptin on insulin resistance in patients with type 2 diabetes mellitus(T2DM).Method:From January 2021 to September 2023,80 patients with T2DM admitted to Guixi People's Hospital were selected as the subjects.They were randomly assigned to the treatment group and the control group,with 40 cases in each group.The treatment group was treated with Voglibose combined with Sitagliptin,while the control group was treated with Sitagliptin alone.All patients were treated for two months.The two groups were compared on blood glucose[fasting blood glucose(FBG),2-hour postprandial blood glucose(2 h PG)and glycated hemoglobin(HbA1c)],insulin function[fasting insulin(FINS),insulin resistance index(HOMA-IR)and insulin beta-cell function(HOMA-β)]before and after treatment,clinical effects,and adverse reactions.Result:After treatment,the levels of FBG,2 h PG and HbA1c in the two groups were significantly decreased(P<0.05),and those in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of FINS and HOMA-IR in the two groups were significantly decreased,and the levels of HOMA-β were significantly increased(P<0.05),and those in the treatment group were better than those in the control group,the differences were statistically significant(P<0.05).The total effective rate of the treatment group was higher than that of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment with Voglibose and Sitagliptin can significantly reduce blood glucose levels and effectively improve insulin resistance in patients with T2DM,the overall effect is outstanding,and the safety is high.
国家科技期刊平台
NSTL
万方数据
